Vimarsana
Biggest News Aggregation in the World

Page 31 - Updated March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Updated March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Updated March Today - Breaking & Trending Today

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML - Vimarsana News

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...

Tips to Help Patients Manage Hypertension - Vimarsana News

Tips to Help Patients Manage Hypertension

Identification is key: this silent disease can lead to complications.

Mental Health Care for Women of Color: Risk Factors, Barriers, and Clinical Recommendations - Vimarsana News

Mental Health Care for Women of Color: Risk Factors, Barriers, and Clinical Recommendations

It is essential that clinicians take an active approach in creating a culturally safe space to provide mental health care to WoC.

FDA approves Bayer's Ultravist (iopromide) Injection for Contrast-enhanced Mammography - Vimarsana News

FDA approves Bayer's Ultravist (iopromide) Injection for Contrast-enhanced Mammography

Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent 

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography | Business - Vimarsana News

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography | Business

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 23, 2023--